1. What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

3. Program Overview

4. Managing Stable COPD: Goals of Therapy

5. Updated GOLD Recommendations: First-line Pharmacologic Therapy for Stable COPD

6. Real-Life ICS Use in COPD: Adherence to Guidelines in France

10. Available and Emerging LABA and LAMA Bronchodilators for COPD

11. β2-Agonists and Muscarinic Antagonists in COPD: Sites of Action

12. Effect of Indacaterol vs Blinded Tiotropium on Trough FEV1: INTENSITY

13. Single Dose of Umeclidinium/Vilanterol vs Single-Agent Components or Placebo

14. Considerations When Switching or Stepping Up Therapy

15. Health Status and Symptoms for Tiotropium + Olodaterol vs Monocomponents

16. Annualized Rate of Moderate or Severe Exacerbations: SPARK

17. Lung Function Improvement With Umeclidinium/Vilanterol vs Fluticasone/Salmeterol

18. Effect of ICS on Preventing COPD Exacerbations

19. Use of ICS and Risk for Pneumonia: Dose-Response Relationship

20. Real-World Management for COPD Population in the United Kingdom

21. ICS Withdrawal and Exacerbations in Patients With Severe COPD: WISDOM

22. Time to First Moderate or Severe COPD Exacerbation for Indacaterol/Glycopyrronium vs Salmeterol/Fluticasone

23. Improvements in SGRQ Score for Salmeterol/Fluticasone With or Without Glycopyrronium or Tiotropium

24. A PCP Approach to Monotherapy for COPD

25. A Pulmonologist’s View of COPD Treatment

26. Move Towards Phenotype-Directed Treatment?

27. Take-Home Messages

28. Take-Home Messages (cont)

29. Abbreviations

30. Abbreviations

31. References

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)